Company research / TVTX

Travere Therapeutics, Inc. (TVTX)

CIK 0001438533 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated CA
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Travere Therapeutics, Inc. reported revenue of $490.73M. Revenue grew 110.5% from the prior annual period.

Key ratios (year ended 2025-12-31)

-12.8%
Operating margin
-5.2%
Net margin
-22.2%
Return on year-end equity
110.5%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4 · 2026-09-03

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.